{ "schemaVersion": 2, "eyebrow": "Hepatology", "title": "Hepatic Encephalopathy Treatment Escalation", "summary": "Escalate hepatic encephalopathy care by protecting the airway in severe impairment, correcting reversible precipitants, using lactulose as first-line therapy, and adding rifaximin for recurrent overt episodes. Persistent or recurrent encephalopathy requires reassessment for ongoing triggers, treatment adherence, and portosystemic shunting.", "seoDescription": "Physician guide to escalating hepatic encephalopathy treatment: airway protection, precipitant correction, lactulose, rifaximin, and recurrence prevention.", "clinicalQuestion": "How should clinicians escalate treatment for overt hepatic encephalopathy that recurs or fails to improve with initial therapy?", "specialty": "Hepatology", "audience": "U.S. physicians and medical trainees", "tags": [ "hepatic encephalopathy", "overt hepatic encephalopathy", "lactulose", "rifaximin", "cirrhosis", "treatment escalation", "secondary prophylaxis" ], "keyTakeaways": [ "Treat every overt hepatic encephalopathy episode actively while identifying and reversing a precipitating condition; infection, gastrointestinal bleeding, volume loss, constipation, electrolyte disturbance, renal dysfunction, hypoxia, and sedative or alcohol exposure are high-yield targets. [1][21]", "Prioritize airway protection when impaired consciousness compromises airway safety; severe overt hepatic encephalopathy may progress to coma. [2][7]", "Use lactulose as first-line therapy for episodic overt hepatic encephalopathy and continue it for secondary prevention after an initial episode when tolerated. [12][21]", "Add rifaximin 550 mg orally twice daily to lactulose to reduce recurrence after recurrent overt hepatic encephalopathy; it is generally initiated after acute episode resolution and may be started during hospitalization. [21][23]", "Failure to improve should trigger a renewed search for persistent precipitants and competing neurologic, metabolic, toxic, or respiratory causes of altered mental status rather than empiric substitution of standard therapy. [1]" ], "sections": [ { "id": "stabilize-and-identify-urgent-threats", "eyebrow": "Immediate management", "heading": "Stabilize severe overt hepatic encephalopathy before enteral therapy", "intro": "The first escalation decision is whether mental status impairment makes airway protection unsafe.", "paragraphs": [ "Protect the airway when depressed consciousness or loss of protective reflexes creates aspiration risk. Airway protection is specifically emphasized in decompensated cirrhosis admissions, and overt hepatic encephalopathy can range from subtle neuropsychiatric impairment to profound coma. [2][7]", "Do not attribute acute altered mental status automatically to hepatic encephalopathy. Reassess for intracranial hematoma or cerebrovascular accident, encephalitis, thyroid dysfunction, hypoglycemia, hypoxia, hypercapnia, sedative, narcotic, psychotropic drug, or alcohol intoxication, and acid-base disturbance; each may mimic, coexist with, or worsen encephalopathy and requires cause-directed management. [1]", "Once airway safety and immediate competing emergencies have been addressed, begin treatment for the overt episode rather than waiting for every precipitant study to return. Guidelines summarized in long-term management evidence recommend active treatment whether the episode is spontaneous or precipitated. [21]" ], "bullets": [ "Escalate level of monitoring when consciousness is deteriorating or airway protection is in question. [2]", "Check for hypoglycemia, hypoxia, hypercapnia, drug or alcohol intoxication, and intracranial or central nervous system disease when the presentation is atypical, focal, abrupt, or disproportionate to prior hepatic encephalopathy. [1]", "Review recent sedatives, narcotics, psychotropic drugs, alcohol, diuretics, fluid restriction, vomiting, diarrhea, paracentesis, surgery, and dietary or bowel changes. [1]" ], "subsections": [], "table": { "caption": "Immediate escalation targets in acute altered mental status with cirrhosis. [1][2]", "columns": [ "Finding or context", "Action that changes immediate care" ], "rows": [ [ "Impaired airway protection or profoundly depressed consciousness", "Prioritize airway protection and monitored care before oral treatment. [2]" ], [ "Hypoglycemia, hypoxia, hypercapnia, drug intoxication, intracranial event, or encephalitis suspected", "Evaluate and treat the competing cause; do not presume hepatic encephalopathy is the sole explanation. [1]" ], [ "Overt hepatic encephalopathy with concurrent bleeding, sepsis, hypovolemia, renal dysfunction, constipation, or electrolyte disturbance", "Treat the encephalopathy and reverse the precipitant in parallel. [1][21]" ] ] } }, { "id": "find-and-reverse-precipitants", "eyebrow": "Parallel workup", "heading": "Use precipitant-directed escalation rather than ammonia-lowering therapy alone", "intro": "A persistent trigger commonly explains incomplete response or early recurrence.", "paragraphs": [ "Search systematically for infection and gastrointestinal hemorrhage, particularly spontaneous bacterial peritonitis, fever or sepsis, anemia from acute or chronic gastrointestinal bleeding, and hypotension or hypovolemia from bleeding, shock, peripheral vasodilation, overdiuresis, diarrhea, vomiting, or paracentesis. These conditions are recognized concurrent causes and precipitants of encephalopathy. [1]", "Correct constipation, dehydration, acid-base disorders, hyponatremia, hypokalemia, uremia or azotemia, and medication-related neurodepression. Protein restriction is no longer recommended as a response to encephalopathy; excessive protein intake is listed as a potential precipitant, but restriction is not recommended. [1]", "When encephalopathy persists despite correction of an identified precipitant and standard therapy, repeat the medication and exposure review, reassess volume status and renal function, and revisit alternative neurologic, metabolic, and respiratory diagnoses. This approach is particularly important after surgery, when several listed drivers may coexist. [1]" ], "bullets": [ "Infection branch: evaluate for sepsis or fever and, in a patient with ascites, consider spontaneous bacterial peritonitis as a precipitant. [1]", "Bleeding branch: investigate anemia, hemodynamic compromise, and gastrointestinal bleeding; bleeding can precipitate encephalopathy through hypovolemia and anemia. [1]", "Volume and kidney branch: identify diuretic exposure, fluid restriction, diarrhea, vomiting, recent paracentesis, hypotension, uremia, or azotemia. [1]", "Bowel and medication branch: address constipation and remove or reduce sedatives, narcotics, psychotropic agents, and alcohol exposure when possible. [1]" ], "subsections": [], "table": { "caption": "Precipitants that should redirect escalation in overt hepatic encephalopathy. [1]", "columns": [ "Etiologic branch", "Clues to seek", "Next action" ], "rows": [ [ "Infection", "Fever, sepsis, spontaneous bacterial peritonitis", "Identify and treat the infection while continuing hepatic encephalopathy therapy. [1]" ], [ "Gastrointestinal bleeding", "Anemia, hypotension, hypovolemia, acute or chronic gastrointestinal blood loss", "Treat bleeding and restore effective circulation; do not manage as isolated encephalopathy. [1]" ], [ "Volume, renal, or electrolyte disorder", "Diuretics, vomiting, diarrhea, paracentesis, dehydration, hyponatremia, hypokalemia, uremia, azotemia", "Correct the identified disturbance and reassess mental status. [1]" ], [ "Medication or substance effect", "Sedatives, narcotics, psychotropic drugs, alcohol", "Stop, reduce, or reverse the implicated exposure when clinically feasible and reassess for an alternative diagnosis. [1]" ], [ "Constipation", "Reduced bowel activity or inadequate laxative titration", "Restore bowel activity and reinforce chronic lactulose titration after recovery. [1][3]" ] ] } }, { "id": "first-line-acute-therapy", "eyebrow": "Initial pharmacotherapy", "heading": "Use lactulose as the foundation of overt episode treatment", "intro": "Lactulose remains the preferred first-line therapy for episodic overt hepatic encephalopathy.", "paragraphs": [ "Use lactulose as first-choice therapy for episodic hepatic encephalopathy. Nonabsorbable disaccharides, including lactulose and lactitol, are recommended as first-line treatment, and guideline summaries identify lactulose as the first choice for both episodic treatment and prevention of recurrent episodes after the initial episode. [12][21]", "The practical escalation problem is usually inadequate delivery or titration rather than a need to abandon lactulose immediately. Patients receiving chronic lactulose should be counseled to titrate treatment to their target number of bowel movements per day; inadequate titration has been identified as a common contributor to preventable readmission. [3]", "If recurrent episodes occur on lactulose, first establish whether the patient is taking and titrating the drug consistently and whether constipation or another precipitant is still present. Inadequate adherence is a major limitation of lactulose therapy. [3][7]" ], "bullets": [ "Treat an overt episode with lactulose while correcting precipitants rather than using precipitant treatment as a substitute for encephalopathy therapy. [21]", "Continue lactulose chronically for secondary prophylaxis in patients with cirrhosis or portal hypertension who tolerate it and have had previous or recurrent hepatic encephalopathy. [3]", "Reinforce patient and caregiver-directed titration instructions at discharge because under-titration contributes to recurrence and readmission. [3]" ], "subsections": [], "table": { "caption": "Lactulose decisions across the overt hepatic encephalopathy course. [3][12][21]", "columns": [ "Clinical situation", "Lactulose role", "Escalation decision" ], "rows": [ [ "Active episodic overt hepatic encephalopathy", "First-choice therapy. [12][21]", "Start or continue treatment while searching for precipitants. [21]" ], [ "After a first overt episode", "Recommended for prevention of recurrent episodes when tolerated. [21]", "Transition to chronic secondary prophylaxis with explicit titration counseling. [3]" ], [ "Recurrent encephalopathy on prescribed lactulose", "Assess tolerance, adherence, and titration before declaring treatment failure. [3][7]", "Correct adherence or precipitant problems and add rifaximin when recurrence criteria are met. [21][23]" ] ] } }, { "id": "add-rifaximin-for-recurrence", "eyebrow": "Recurrence prevention", "heading": "Add rifaximin after recurrent overt hepatic encephalopathy", "intro": "Rifaximin is the key pharmacologic escalation when recurrence occurs despite lactulose-based management.", "paragraphs": [ "Add rifaximin to lactulose for secondary prophylaxis after recurrent overt hepatic encephalopathy. AASLD and EASL guidance summarized in the available evidence recommends rifaximin as an effective add-on after the second overt episode, while another guideline summary describes add-on treatment following at least one overt episode within 6 months of the first in patients with episodic disease. [3][21]", "Use rifaximin 550 mg orally twice daily. It is often started after acute episode resolution and may be initiated during the hospitalization; its approved use is prevention of recurrent hepatic encephalopathy. [23]", "Do not substitute rifaximin for correction of an active precipitant. Recurrent encephalopathy despite lactulose should prompt both rifaximin addition and a check for infection, bleeding, constipation, dehydration, electrolyte disturbance, renal dysfunction, or psychoactive drug exposure. [1][21]", "For lactulose intolerance, ineffectiveness, or adherence failure, rifaximin monotherapy has been proposed in emerging evidence, but the review characterizes this strategy as requiring further research. Combination therapy remains the better-supported escalation approach for recurrence. [21]" ], "bullets": [ "Dose: rifaximin 550 mg orally twice daily for prevention of recurrent overt hepatic encephalopathy. [23]", "Timing: begin after acute improvement or during the index hospitalization when planning secondary prophylaxis. [23]", "Selection: recurrent overt episodes despite lactulose-based management, particularly after a second episode. [21]", "Do not routinely escalate to neomycin; its efficacy evidence is ambiguous and toxicity limits routine use. [7][22]" ], "subsections": [], "table": { "caption": "Drug escalation for recurrent overt hepatic encephalopathy. [3][7][21][23]", "columns": [ "Therapy", "When to use", "Supported regimen or limitation" ], "rows": [ [ "Lactulose", "First-line episodic treatment and secondary prevention after an initial episode. [12][21]", "Chronic therapy requires patient-directed titration to a target bowel-movement frequency. [3]" ], [ "Rifaximin plus lactulose", "Recurrent overt hepatic encephalopathy; guidance summarized as after a second episode or after at least one episode within 6 months of the first. [3][21]", "Rifaximin 550 mg orally twice daily; often started after acute resolution and sometimes during hospitalization. [23]" ], [ "Rifaximin monotherapy", "Consider only when lactulose is ineffective, poorly tolerated, or adherence is problematic. [21]", "Emerging strategy; further research is needed. [21]" ], [ "Neomycin", "Not a routine escalation choice. [22]", "Ambiguous efficacy evidence and significant toxicity concerns. [7][22]" ] ] } }, { "id": "refractory-or-post-tips-encephalopathy", "eyebrow": "Failure of standard escalation", "heading": "Reassess persistent encephalopathy for ongoing triggers and shunt-related disease", "intro": "Persistent encephalopathy should prompt diagnostic re-escalation, not reflexive multiplication of unproven therapies.", "paragraphs": [ "When mental status fails to improve after lactulose-based treatment and precipitant correction, reassess whether the diagnosis is correct and whether a trigger remains untreated. Intracranial pathology, encephalitis, thyroid disease, hypoglycemia, hypoxia, hypercapnia, intoxication, acid-base disorders, renal dysfunction, and electrolyte abnormalities remain competing or concurrent explanations. [1]", "Consider portosystemic shunting as a major structural branch in recurrent or difficult-to-control disease. Hepatic encephalopathy is a syndrome associated with portosystemic venous shunting with or without intrinsic liver disease, and it is a common complication after transjugular intrahepatic portosystemic shunt creation. [7][24]", "Reserve alternative adjunctive approaches for patients not responsive to conventional therapy. Intravenous L-ornithine L-aspartate and oral branched-chain amino acids are described as alternative or additional agents in this setting, whereas probiotics remain investigational for secondary prevention because a placebo-controlled trial showed fewer breakthrough episodes without a statistically significant difference. [4][21]" ], "bullets": [ "Persistent encephalopathy: repeat the precipitant and competing-diagnosis assessment before labeling disease refractory. [1]", "Post-TIPS encephalopathy: recognize the temporal relationship to shunt creation and assess for shunt-related contribution. [24]", "Nonresponse to conventional therapy: intravenous L-ornithine L-aspartate or oral branched-chain amino acids may be used as alternative or add-on agents. [21]", "Avoid assuming probiotics replace lactulose or rifaximin for secondary prevention; controlled evidence cited did not show a statistically significant reduction in breakthrough encephalopathy. [4]" ], "subsections": [], "table": { "caption": "Escalation after inadequate response to lactulose and rifaximin-based care. [1][4][21][24]", "columns": [ "Problem", "What to reassess", "Next management direction" ], "rows": [ [ "No meaningful improvement", "Persistent infection, bleeding, constipation, volume loss, renal dysfunction, electrolyte or acid-base disorder, intoxication, hypoxia, hypercapnia, and nonhepatic neurologic disease. [1]", "Treat the unresolved driver or alternate diagnosis while maintaining standard hepatic encephalopathy therapy. [1][21]" ], [ "Recurrent episodes despite secondary prophylaxis", "Lactulose tolerance, adherence, bowel-movement titration, and an ongoing precipitant. [3][7]", "Ensure lactulose is optimized and add or continue rifaximin 550 mg twice daily. [21][23]" ], [ "Encephalopathy after TIPS", "Relationship to transjugular intrahepatic portosystemic shunt creation. [24]", "Treat as possible shunt-related encephalopathy while evaluating other concurrent precipitants. [1][24]" ], [ "Conventional therapy nonresponse", "Whether standard therapy and precipitant correction have been completed. [21]", "Consider intravenous L-ornithine L-aspartate or oral branched-chain amino acids as alternative or add-on therapy. [21]" ] ] } }, { "id": "discharge-and-long-term-escalation", "eyebrow": "Transition of care", "heading": "Prevent the next episode with medication execution and trigger control", "intro": "Discharge planning should convert the treated episode into durable secondary prophylaxis.", "paragraphs": [ "After overt hepatic encephalopathy resolves, continue secondary prophylaxis rather than stopping therapy at discharge. Lactulose is recommended after an initial episode, and rifaximin is added for recurrent disease; recurrence on lactulose monotherapy has been described as a 40% cumulative risk within 6 months of an initial overt episode. [21][23]", "Give patients and caregivers explicit lactulose titration instructions and confirm the plan before discharge. Preventable readmission has been linked to failure to titrate lactulose adequately, while poor adherence remains a major limitation of lactulose therapy. [3][7]", "Reassess whether prophylactic therapy can ever be withdrawn only when precipitating factors, such as infection and variceal bleeding, have been well controlled. Otherwise, continue prophylaxis and review for recurrent triggers at every breakthrough event. [21]" ], "bullets": [ "Document the prior overt episode and the prophylaxis plan in discharge instructions. [21]", "For recurrent disease, prescribe rifaximin 550 mg orally twice daily in addition to lactulose. [21][23]", "Teach caregivers to recognize constipation, medication exposure, dehydration, bleeding, and infection as recurrence signals requiring early clinical contact. [1][3]", "Maintain prophylaxis unless the precipitating context has been durably controlled. [21]" ], "subsections": [], "table": { "caption": "Secondary prophylaxis decisions after an overt hepatic encephalopathy admission. [1][3][21][23]", "columns": [ "Discharge decision", "Action", "Rationale" ], "rows": [ [ "First overt episode, lactulose tolerated", "Continue chronic lactulose with bowel-movement titration counseling. [3][21]", "Lactulose is recommended for prevention of recurrent overt hepatic encephalopathy after the initial episode. [21]" ], [ "Recurrent overt episodes", "Use rifaximin 550 mg orally twice daily as add-on to lactulose. [21][23]", "Rifaximin reduces recurrence risk and hepatic encephalopathy-related hospitalization in the cited evidence base. [7][21]" ], [ "Breakthrough episode after discharge", "Assess adherence and titration, then search for infection, bleeding, constipation, volume loss, renal dysfunction, electrolyte disorder, or psychoactive drug exposure. [1][3]", "Most escalation failures require correction of a persistent trigger in addition to drug therapy. [1][21]" ] ] } } ], "faq": [], "references": [ { "number": 1, "title": "[PDF] 22-554 CROSS DISCIPLINE TEAM LEADER REVIEW", "detail": "www.accessdata.fda.gov", "url": "https://www.accessdata.fda.gov/drugsatfda_docs/nda/2010/022554Orig1s000CrossR.pdf", "authors": "www.accessdata.fda.gov", "host": "www.accessdata.fda.gov" }, { "number": 2, "title": "Decompensated cirrhosis: an update of the BSG/BASL admission ...", "detail": "fg.bmj.com", "url": "https://fg.bmj.com/content/flgastro/early/2025/04/16/flgastro-2025-103074.full.pdf", "authors": "fg.bmj.com", "host": "fg.bmj.com" }, { "number": 3, "title": "Hepatic encephalopathy - Prevention | BMJ Best Practice", "detail": "bestpractice.bmj.com", "url": "https://bestpractice.bmj.com/topics/en-gb/294/prevention", "authors": "bestpractice.bmj.com", "host": "bestpractice.bmj.com" }, { "number": 4, "title": "Probiotics for Secondary Prevention of Hepatic Encephalopathy? | NEJM Clinician", "detail": "clinician.nejm.org", "url": "https://clinician.nejm.org/probiotics-secondary-prevention-hepatic-encephalopathy-nejm-jw.NA36530", "authors": "clinician.nejm.org", "host": "clinician.nejm.org" }, { "number": 5, "title": "Mechanisms, diagnosis and management of hepatic encephalopathy", "detail": "www.nature.com", "url": "https://www.nature.com/articles/nrgastro.2010.116", "authors": "www.nature.com", "host": "www.nature.com" }, { "number": 6, "title": "Advances in the management of complications from cirrhosis", "detail": "academic.oup.com", "url": "https://academic.oup.com/gastro/article/doi/10.1093/gastro/goae072/7727525", "authors": "academic.oup.com", "host": "academic.oup.com" }, { "number": 7, "title": "Analysis of Hospitalizations Comparing Rifaximin Versus Lactulose in the Management of Hepatic Encephalopathy", "detail": "www.sciencedirect.com", "url": "https://www.sciencedirect.com/science/article/abs/pii/S0041134506013364", "authors": "www.sciencedirect.com", "host": "www.sciencedirect.com" }, { "number": 8, "title": "Management of Overt Hepatic Encephalopathy - ScienceDirect", "detail": "www.sciencedirect.com", "url": "https://www.sciencedirect.com/science/article/abs/pii/S0973688314002916", "authors": "www.sciencedirect.com", "host": "www.sciencedirect.com" }, { "number": 9, "title": "[PDF] Guidelines for the Prevention and Treatment of Opportunistic ...", "detail": "clinicalinfo.hiv.gov", "url": "https://clinicalinfo.hiv.gov/sites/default/files/guidelines/archive/adult-adolescent-oi-2025-09-09.pdf", "authors": "clinicalinfo.hiv.gov", "host": "clinicalinfo.hiv.gov" }, { "number": 10, "title": "Branched‐chain amino acids for people with hepatic encephalopathy", "detail": "www.cochranelibrary.com", "url": "https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD001939.pub4/full", "authors": "www.cochranelibrary.com", "host": "www.cochranelibrary.com" }, { "number": 11, "title": "Probiotics for people with hepatic encephalopathy - Dalal, R - 2017", "detail": "www.cochranelibrary.com", "url": "https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD008716.pub3/references", "authors": "www.cochranelibrary.com", "host": "www.cochranelibrary.com" }, { "number": 12, "title": "Non‐absorbable disaccharides versus placebo/no intervention and ...", "detail": "www.cochranelibrary.com", "url": "https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD003044.pub4/full", "authors": "www.cochranelibrary.com", "host": "www.cochranelibrary.com" }, { "number": 13, "title": "نقش ریفاکسیمین در پیشگیری و درمان انسفالوپاتی کبدی در افراد ...", "detail": "www.cochranelibrary.com", "url": "https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD011585.pub2/references/fa", "authors": "www.cochranelibrary.com", "host": "www.cochranelibrary.com" }, { "number": 14, "title": "Neurophysiologic and Psychometric Tests in the Diagnosis of Low ...", "detail": "www.gastrojournal.org", "url": "https://www.gastrojournal.org/article/S0016-5085(15)00004-9/fulltext", "authors": "www.gastrojournal.org", "host": "www.gastrojournal.org" }, { "number": 15, "title": "Value of Critical Flicker Frequency and Psychometric Hepatic ...", "detail": "www.gastrojournal.org", "url": "https://www.gastrojournal.org/article/S0016-5085(13)01839-8/pdf", "authors": "www.gastrojournal.org", "host": "www.gastrojournal.org" }, { "number": 16, "title": "[PDF] EASL Clinical Practice Guidelines for the management of patients ...", "detail": "easl.eu", "url": "https://easl.eu/wp-content/uploads/2018/10/decompensated-cirrhosis-English-report.pdf", "authors": "easl.eu", "host": "easl.eu" }, { "number": 17, "title": "Deciphering the Spectrum of Low-Grade Hepatic Encephalopathy in ...", "detail": "www.gastrojournal.org", "url": "https://www.gastrojournal.org/article/S0016-5085(14)00230-3/pdf", "authors": "www.gastrojournal.org", "host": "www.gastrojournal.org" }, { "number": 18, "title": "Hepatic Encephalopathy: Current and Emerging Treatment Modalities", "detail": "www.gastrojournal.org", "url": "https://www.gastrojournal.org/article/S1542-3565(22)00462-1/fulltext", "authors": "www.gastrojournal.org", "host": "www.gastrojournal.org" }, { "number": 19, "title": "ClinicalTrials.gov", "detail": "clinicaltrials.gov", "url": "https://clinicaltrials.gov/study/NCT05433948", "authors": "clinicaltrials.gov", "host": "clinicaltrials.gov" }, { "number": 20, "title": "[PDF] Clinical Study Protocol - ClinicalTrials.gov", "detail": "cdn.clinicaltrials.gov", "url": "https://cdn.clinicaltrials.gov/large-docs/41/NCT02097641/Prot_SAP_000.pdf", "authors": "cdn.clinicaltrials.gov", "host": "cdn.clinicaltrials.gov" }, { "number": 21, "title": "Long-term management of hepatic encephalopathy with lactulose and/or rifaximin: a review of the evidence - PMC", "detail": "www.ncbi.nlm.nih.gov", "url": "https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6416096", "authors": "www.ncbi.nlm.nih.gov", "host": "www.ncbi.nlm.nih.gov" }, { "number": 22, "title": "4 Consideration of the evidence | Rifaximin for preventing episodes of overt hepatic encephalopathy | Guidance | NICE", "detail": "www.nice.org.uk", "url": "https://www.nice.org.uk/guidance/ta337/chapter/4-consideration-of-the-evidence", "authors": "www.nice.org.uk", "host": "www.nice.org.uk" }, { "number": 23, "title": "Why do we use Lactulose and Rifaximin for Hepatic Encephalopathy?", "detail": "www.aasld.org", "url": "https://www.aasld.org/liver-fellow-network/core-series/why-series/why-do-we-use-lactulose-and-rifaximin-hepatic", "authors": "www.aasld.org", "host": "www.aasld.org" }, { "number": 24, "title": "TIPS-related Hepatic Encephalopathy: Management Options with ...", "detail": "pubs.rsna.org", "url": "https://pubs.rsna.org/doi/10.1148/rg.241035028", "authors": "pubs.rsna.org", "host": "pubs.rsna.org" } ], "editorialNote": "Prepared from cited clinical literature using Astra's research workflow. Verify recommendations against current guidance and patient-specific factors.", "citations": [ { "number": 1, "title": "[PDF] 22-554 CROSS DISCIPLINE TEAM LEADER REVIEW", "detail": "www.accessdata.fda.gov", "url": "https://www.accessdata.fda.gov/drugsatfda_docs/nda/2010/022554Orig1s000CrossR.pdf", "authors": "www.accessdata.fda.gov", "host": "www.accessdata.fda.gov", "snippet": "83 APPENDIX 3 84 APPENDIX 4 NDA 22-554 Comprehensive list of MICs for rifaximin against clinical isolates APPENDIX 5 NDA 22-554 Common Precipitating Factors and Concurrent Causes of Encephalopathy Intracranial hematomas, cerebral vascular accident Encephalitis Thyroid dysfunction Hypoglycemia Hypoxi", "score": 0.98566 }, { "number": 2, "title": "Decompensated cirrhosis: an update of the BSG/BASL admission ...", "detail": "fg.bmj.com", "url": "https://fg.bmj.com/content/flgastro/early/2025/04/16/flgastro-2025-103074.full.pdf", "authors": "fg.bmj.com", "host": "fg.bmj.com", "snippet": "Octreotide to be considered for those with contraindication to Terlipressin. Hepatic encephalopathy ... Airway protection is vital", "score": 0.98126 }, { "number": 3, "title": "Hepatic encephalopathy - Prevention | BMJ Best Practice", "detail": "bestpractice.bmj.com", "url": "https://bestpractice.bmj.com/topics/en-gb/294/prevention", "authors": "bestpractice.bmj.com", "host": "bestpractice.bmj.com", "snippet": "Title: Hepatic encephalopathy - Prevention | BMJ Best Practice\n# Hepatic encephalopathy. Prophylactic treatment with lactulose has been shown to be effective for preventing recurrence of HE in patients with cirrhosis.Vilstrup H, Amodio P, Bajaj J, et al. Hepatic encephalopathy in chronic liver disea", "score": 0.78314424 }, { "number": 4, "title": "Probiotics for Secondary Prevention of Hepatic Encephalopathy? | NEJM Clinician", "detail": "clinician.nejm.org", "url": "https://clinician.nejm.org/probiotics-secondary-prevention-hepatic-encephalopathy-nejm-jw.NA36530", "authors": "clinician.nejm.org", "host": "clinician.nejm.org", "snippet": "To find out, investigators randomized 130 patients with cirrhosis and a previous HE episode to receive the probiotic VSL#3 or placebo daily for 6 months in a double-blinded, industry-funded study. Other HE medications such as lactulose and rifaximin were stopped a week prior to randomization. The pr", "score": 0.33613545 }, { "number": 5, "title": "Mechanisms, diagnosis and management of hepatic encephalopathy", "detail": "www.nature.com", "url": "https://www.nature.com/articles/nrgastro.2010.116", "authors": "www.nature.com", "host": "www.nature.com", "snippet": "The different grades of HE can be diagnosed by a number of investigations, including neuropsychometric tests (such as the psychometric hepatic", "score": 0.9742 }, { "number": 6, "title": "Advances in the management of complications from cirrhosis", "detail": "academic.oup.com", "url": "https://academic.oup.com/gastro/article/doi/10.1093/gastro/goae072/7727525", "authors": "academic.oup.com", "host": "academic.oup.com", "snippet": "While lactulose and rifaximin are the preferred treatments for hepatic encephalopathy, many alternative treatment options may be used in", "score": 0.98172 }, { "number": 7, "title": "Analysis of Hospitalizations Comparing Rifaximin Versus Lactulose in the Management of Hepatic Encephalopathy", "detail": "www.sciencedirect.com", "url": "https://www.sciencedirect.com/science/article/abs/pii/S0041134506013364", "authors": "www.sciencedirect.com", "host": "www.sciencedirect.com", "snippet": "Inadequate compliance is the major limitation of lactulose therapy. Inhibition of production of ammonia or other neurotoxins by intestinal bacteria has promoted the use of antibiotics, such as neomycin, metronidazole, vancomycin, and rifaximin [37,40,41,50–56]. The evidence for efficacy of neomycin ", "score": 0.588062 }, { "number": 8, "title": "Management of Overt Hepatic Encephalopathy - ScienceDirect", "detail": "www.sciencedirect.com", "url": "https://www.sciencedirect.com/science/article/abs/pii/S0973688314002916", "authors": "www.sciencedirect.com", "host": "www.sciencedirect.com", "snippet": "### J Hepatol\n\n### Rifaximin in the treatment of chronic hepatic encephalopathy: results of a multicenter study of efficacy and safety\n\n### Curr Ther Res\n\n### Comparison of rifaximin and lactitol in the treatment of acute hepatic encephalopathy: results of a randomized, double-blind, double-dummy, c", "score": 0.5059329 }, { "number": 9, "title": "[PDF] Guidelines for the Prevention and Treatment of Opportunistic ...", "detail": "clinicalinfo.hiv.gov", "url": "https://clinicalinfo.hiv.gov/sites/default/files/guidelines/archive/adult-adolescent-oi-2025-09-09.pdf", "authors": "clinicalinfo.hiv.gov", "host": "clinicalinfo.hiv.gov", "snippet": "and then every 1 year to 2 years to identify substantial gastroesophageal varices (see the American Association for the Study of Liver Diseases (AASLD) 2018 Hepatitis B Guidance). People with varices require nonselective beta blockers—such as nadolol or propranolol—that are the mainstay of both prim", "score": 0.59372765 }, { "number": 10, "title": "Branched‐chain amino acids for people with hepatic encephalopathy", "detail": "www.cochranelibrary.com", "url": "https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD001939.pub4/full", "authors": "www.cochranelibrary.com", "host": "www.cochranelibrary.com", "snippet": "Recent guidelines recommend routine treatment of people with overt hepatic encephalopathy (AASLD and EASL guideline 2014a; AASLD and EASL", "score": 0.5518883 }, { "number": 11, "title": "Probiotics for people with hepatic encephalopathy - Dalal, R - 2017", "detail": "www.cochranelibrary.com", "url": "https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD008716.pub3/references", "authors": "www.cochranelibrary.com", "host": "www.cochranelibrary.com", "snippet": "Guideline for good clinical practice CFR & ICH Guidelines. Vol. 1 ... On current therapy for prevention or treatment of overt hepatic encephalopathy.", "score": 0.47373086 }, { "number": 12, "title": "Non‐absorbable disaccharides versus placebo/no intervention and ...", "detail": "www.cochranelibrary.com", "url": "https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD003044.pub4/full", "authors": "www.cochranelibrary.com", "host": "www.cochranelibrary.com", "snippet": "Non‐absorbable disaccharides (lactulose and lactitol) are recommended as first‐line treatment for hepatic encephalopathy. The previous (second)", "score": 0.41250706 }, { "number": 13, "title": "نقش ریفاکسیمین در پیشگیری و درمان انسفالوپاتی کبدی در افراد ...", "detail": "www.cochranelibrary.com", "url": "https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD011585.pub2/references/fa", "authors": "www.cochranelibrary.com", "host": "www.cochranelibrary.com", "snippet": "Rifaximin versus placebo preventing the recurrence of clinically overt hepatic encephalopathy in patients having cirrhosis of liver.", "score": 0.38623142 }, { "number": 14, "title": "Neurophysiologic and Psychometric Tests in the Diagnosis of Low ...", "detail": "www.gastrojournal.org", "url": "https://www.gastrojournal.org/article/S0016-5085(15)00004-9/fulltext", "authors": "www.gastrojournal.org", "host": "www.gastrojournal.org", "snippet": "Using a computerized psychometric testing. CFF and PHES are not optimal to identify minimal hepatic encephalopathy (MHE). by West Haven criteria)", "score": 0.98537 }, { "number": 15, "title": "Value of Critical Flicker Frequency and Psychometric Hepatic ...", "detail": "www.gastrojournal.org", "url": "https://www.gastrojournal.org/article/S0016-5085(13)01839-8/pdf", "authors": "www.gastrojournal.org", "host": "www.gastrojournal.org", "snippet": "Critical flicker frequency (CFF) and psychometric hepatic encephalopathy score (PHES) analyses are widely used to diagnose hepatic encephalopathy (HE),", "score": 0.9845 }, { "number": 16, "title": "[PDF] EASL Clinical Practice Guidelines for the management of patients ...", "detail": "easl.eu", "url": "https://easl.eu/wp-content/uploads/2018/10/decompensated-cirrhosis-English-report.pdf", "authors": "easl.eu", "host": "easl.eu", "snippet": "EASL Clinical Practice Guidelines for the management of patients with decompensated cirrhosisq European Association for the Study of the Liver ⇑ Summary The natural history of cirrhosis is characterised by an asymp-tomatic compensated phase followed by a decompensated phase, marked by the developmen", "score": 0.97635 }, { "number": 17, "title": "Deciphering the Spectrum of Low-Grade Hepatic Encephalopathy in ...", "detail": "www.gastrojournal.org", "url": "https://www.gastrojournal.org/article/S0016-5085(14)00230-3/pdf", "authors": "www.gastrojournal.org", "host": "www.gastrojournal.org", "snippet": "West Haven criteria and Glasgow coma scale have been used widely in determining overt HE staging. using psychometric tests. This MHE, in the middle of the", "score": 0.9692 }, { "number": 18, "title": "Hepatic Encephalopathy: Current and Emerging Treatment Modalities", "detail": "www.gastrojournal.org", "url": "https://www.gastrojournal.org/article/S1542-3565(22)00462-1/fulltext", "authors": "www.gastrojournal.org", "host": "www.gastrojournal.org", "snippet": "HE is classified into 5 categories including minimal and grade 1 (covert HE) and grade 2–4 (overt HE) according to West Haven Criteria (Table", "score": 0.96496 }, { "number": 19, "title": "ClinicalTrials.gov", "detail": "clinicaltrials.gov", "url": "https://clinicaltrials.gov/study/NCT05433948", "authors": "clinicaltrials.gov", "host": "clinicaltrials.gov", "snippet": "Liver cirrhosis and overt hepatic encephalopathy. West Haven grade 2 or more. n=50. Intervention/Treatment, Diagnostic Test : Simultaneous EEG and CRT. EEG is", "score": 0.96186 }, { "number": 20, "title": "[PDF] Clinical Study Protocol - ClinicalTrials.gov", "detail": "cdn.clinicaltrials.gov", "url": "https://cdn.clinicaltrials.gov/large-docs/41/NCT02097641/Prot_SAP_000.pdf", "authors": "cdn.clinicaltrials.gov", "host": "cdn.clinicaltrials.gov", "snippet": "Clinical Study Protocol Protocol Title: A Phase 1 / 2, Randomized, Double-blind, Placebo-controlled, Multi-center Clinical Trial of Allogeneic Bone Marrow-derived Human Mesenchymal Stem Cells for the Treatment of Acute Respiratory Distress Syndrome Investigational Drug: Allogeneic Bone Marrow-derive", "score": 0.94632 }, { "number": 21, "title": "Long-term management of hepatic encephalopathy with lactulose and/or rifaximin: a review of the evidence - PMC", "detail": "www.ncbi.nlm.nih.gov", "url": "https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6416096", "authors": "www.ncbi.nlm.nih.gov", "host": "www.ncbi.nlm.nih.gov", "snippet": "Current guidelines recommend that an episode of OHE (whether spontaneous or precipitated) should be actively treated, and that secondary prophylaxis should be initiated after an episode to prevent recurrence 1. Lactulose is recommended as the first choice for treatment of episodic HE, and for the pr", "score": 0.79637206 }, { "number": 22, "title": "4 Consideration of the evidence | Rifaximin for preventing episodes of overt hepatic encephalopathy | Guidance | NICE", "detail": "www.nice.org.uk", "url": "https://www.nice.org.uk/guidance/ta337/chapter/4-consideration-of-the-evidence", "authors": "www.nice.org.uk", "host": "www.nice.org.uk", "snippet": "The Committee considered the clinical management of hepatic encephalopathy. The Committee heard from the clinical experts that after an episode of overt hepatic encephalopathy, it was important to prevent or reduce the recurrence of overt episodes, which may be fatal. It heard that rifaximin was the", "score": 0.6954834 }, { "number": 23, "title": "Why do we use Lactulose and Rifaximin for Hepatic Encephalopathy?", "detail": "www.aasld.org", "url": "https://www.aasld.org/liver-fellow-network/core-series/why-series/why-do-we-use-lactulose-and-rifaximin-hepatic", "authors": "www.aasld.org", "host": "www.aasld.org", "snippet": "A meta-analysis of 19 studies comparing rifaximin versus placebo or other interventions (lactulose or other antibiotics) found that rifaximin had a benefit on recovery from HE, prevention of recurrence, and on mortality (see the risk ratio for mortality benefit below).\n\n\n\nThough rifaximin’s only app", "score": 0.6651719 }, { "number": 24, "title": "TIPS-related Hepatic Encephalopathy: Management Options with ...", "detail": "pubs.rsna.org", "url": "https://pubs.rsna.org/doi/10.1148/rg.241035028", "authors": "pubs.rsna.org", "host": "pubs.rsna.org", "snippet": "Hepatic encephalopathy is a common complication that develops after creation of a transjugular intrahepatic portosystemic shunt (TIPS).", "score": 0.5157425 } ], "publishedAt": "2026-09-15T18:41:12.693572+00:00", "updatedAt": "2026-09-15T18:41:12.693572+00:00", "readingMinutes": 6, "slug": "hepatic-encephalopathy-treatment-escalation" }